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Abstract  
 
Brain-derived neurotrophic factor (BDNF) is a key factor in learning and memory. 
Altered BDNF-signalling is thought to contribute to the pathogenesis of schizophrenia 
and major depression (SZ) especially in relation to cognitive deficits. However, 
analysis of serum BDNF as a potential biomarker in psychiatry has provided 
controversial data. We hypothesized that these confounding results might be due to a 
differential regulation of BDNF precursor pro-BDNF (32 KDa) and proteolytic 
products mature (mat-BDNF; 14 KDa), and truncated-BDNF (28 KDa).  
Because of these discrepancies, we decided to perform a systematic review and a 
meta-analysis of studies measuring serum concentrations of BDNF to elucidate 
whether or not this neurotrophin is abnormally produced in patients with 
schizophrenia.  
Additionally, we were interested in identifying factors that might contribute to the 
different findings in literature, as to improve the design of future investigations in this 
field.  
 
In the second part of thesis, we investigated the serum abundance of these BDNF 
isoforms and its relationship with cognitive impairment in schizophrenia. 
Schizophrenia was diagnosed with PANSS test. Abbreviated cognitive assessment 
included tests for attention, perceptualmotor skills, processing speed and memory. 
Using an ELISA assay, we found a slight reduction in serum BDNF levels in SZ 
patients (n ¼ 40) with respect to healthy controls (HC, n = 40; p = 0.018).Western-
blot analysis revealed increased serum pro-BDNF and mat-BDNF and reduced 
truncated-BDNF (p < 0.001) in SZ with respect to HC. Patients with an increase in 
pro-BDNF (n = 15/40) or mat-BDNF (n = 9/40) higher than the HC mean + 2 
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Standard Deviations (SD) also had >2SD reduction of truncated-BDNF (n = 27/40). 
Reduced truncated-BDNF correlated significantly with higher positive and lower 
negative PANNS scores and a worst performance in all cognitive assays but not with 
antipsychotic type. Measurement of serum truncated-BDNF abundance predicted for 
high cognitive deficits with sensitivity ¼ 67.5%, specificity ¼ 97.5%, Negative 
Predictive Value = 75% and Positive Predictive Value = 96.4%. These results 
suggest deficiency in pro-BDNF processing as a possible biological mechanism 
underlying schizophrenia with cognitive impairment. Finally, future perspectives on 
the use of proBDNF as a novel biomarker for psychiatric disorders will be discussed. 
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1. Introduction 
In the last three decades,  a growing body of researches on cognition in 
neurodegenerative disorders, such as schizophrenia and Alzheimer‘s disease (AD), 
have been conducted. Several lines of evidence suggested that  cognitive 
impairment significantly affects quality of life and global functioning in these clinical 
pictures, potentially more than other behavioral or positive symptoms (i.e. 
hallucinations or delusions) (Nuechterlein et al., 2011). One attractive candidate for 
modulating synaptic plasticity in cognitive processes as learning and memory is the 
Brain Derived Neurotrophic Factor (BDNF). The BDNF is a member of the 
neurotrophins‘ family, which includes the Nerve Growth Factor (NGF), the 
Neurotrophin-3 (NT-3)and the NT-4/5.  
 
 
 
 
 
 
 
 
Figure. 1 Neurotrophins and their receptors. 
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Figure 2. Transductional mechanism of action of neurotrophins and their precursors. 
 
This neurotrophin shighly expressed in the central nervous system (CNS) and 
modulates several forms of synaptic plasticity (Schinder et al., 2000), especially in 
the hippocampus and cortex; additionally, it is involved in dopaminergic (Guillin et al., 
2001), glutamatergic (Carvalho et al., 2008) and serotonergic (Mossner et al., 2000) 
neurotransmitter systems. In particular, BDNF Val66Met allele polymorphisms 
suggested that the BDNF is implicated in human memory. Val66Met mutation results 
in abnormal BDNF packaging  into secretory granules, leading to decreased activity-
dependent BDNF release (Egan et al., 2003). This alteration is associated to 
impaired episodic memory and executive performance (Miyajima et al., 2008; 
Schofield et al., 2009), reduced hippocampal activation (Egan et al., 2003; Hariri et 
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al., 2003; Dempster et al., 2005),and increased risk of AD (Tsai et al., 2004; 2006). 
Ho et al. (2006) showed  that both healthy and schizophrenic Met allele carriers had 
poorer verbal memory performance than their Val/Val subjects, whereas visuo-spatial 
impairment was specifically found inpatients with schizophrenia, but not in healthy 
volunteers. There were significant genotype effects on gray matter volumes within 
brain regions supporting memory and visuo-spatial functioning, with Met-allele-
carriers having smaller parietal, temporal and occipital lobar gray matter. However, 
negative findings have been reported on a recent meta-analysis investigating the 
genetic association between BDNF Val66Met polymorphism and cognition 
(Mandelman et al., 2011). Decreased serum concentration of BDNF has been 
consistently described in AD patients (Einat et al., 2003; Laske et al., 2007; Lee et 
al., 2009; Forlenza et al., 2010) and age-related cognitive decline reflecting a 
decrease in BDNF in subregions of the brain (the frontal cortex, the hippocampus, 
the parietal cortex, the temporal cortex and the entorhinal cortex)  that are primarily 
affected by age-related diseases (Laing et al., 2011). However, these studies on 
serum BDNF levels required further deepening as serum BDNF levels were 
significantly lower in AD patients than those in matched patients with vascular 
dementia and controls, but did not correlate with age or scores in MMSE or 
Functional Assessment Staging (FAST) (Yasutake et al., 2006). Nevertheless, in 
Laske et al. (2006) serum BDNF levels were not predictive of progression to AD or 
cognitive deterioration in MCI, even if the presence of the Met allele was a significant 
predictor of cognitive deterioration in these patients. In opposition to these findings, 
other investigators also reported on increased BDNF levels in patients with MCI and 
early AD (Angelucci et al., 2010). Also, recent clinical trials demonstrated that lithium 
and a cholinesterase inhibitor (donepezil) were able to increase serum BDNF levels 
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in patients with early AD (Leyhe et al.,2009). Increments in BDNF levels may suggest 
that to these drugs have some neurobiological effects in AD and MCI patients (Diniz 
et al.,2009; Forlenza et al., 2010). Niitsu et al. (2011) found no significant differences 
in serum BDNF levels between normal controls and patients with schizophrenia, 
although serum BDNF levels were associated to verbal working memory impairment  
and negative symptoms in patients with schizophrenia. Taking as model previous 
animal studies investigating learning-induced neuroplasticity (Buonomano et al., 
1998), Vinogradov et al. (2009) showned that serum BDNF levels were significantly 
increased among clinically stable, chronically ill schizophrenia patients involved in 
neuroplasticity-based cognitive training. Here, we aimed to systematically review the 
literature 1) to explore the role of proBDNF  in animal models of cognitive impairment 
and 2) to elucidate whether abnormalities of the proBDNF/mBDNF ratio may 
contribute to the pathophysiology of neuropschiatric disorders.  
 
2. BDNF biosynthesis 
 
BDNF is initially synthesized as a precursor protein (prepro-BDNF) in the 
endoplasmic reticulum. Mammalian pro-BDNF precursor is also processed to 
truncated-BDNF 28 KDa (proBDNF) or mature 14 kDa BDNF (mBDNF) following two 
different proteolitic cleavages.  
mBDNF is synthesized in the trans-Golgi by furin (Mowla et al., 2001), or 
extracellularly, by plasmin or matrixmetalloprotease-7 (Lee et al., 2001). proBDNF is 
generated by a specific Ca2++dependent serine proteinase known as Membrane-
bound transcription factor site-1 protease (MBTFS-1), also known as Subtilisin/kexin-
isozyme 1 (SKI-1) (Seidah et al., 1999). proBDNF is not further processed into the 
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mature 14 kDa BDNF form and it represents a true final proteolytic product whose 
function is still unclear. It has long been thought that only secreted mBDNF was 
biologically active, whereas pro-DNF was an inactive precursor localized 
intracellulary. Recent studies demonstrated that mBDNF and pro-BDNF elicited 
opposite biological effects (Teng et al., 2005; Woo et al., 2005). Specifically, mBDNF 
bound Trk-B receptor promoting dendritic spines formation and proBDNF bound p75 
receptor triggering apoptotic processes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Synthesis and sorting of BDNF. 
 
More recently, Koshimizu et al. (2009) found that the overexpression of pro-BDNF 
elicited the apoptosis of cultured cerebellar granule neurons and caused a dramatic 
reduction in the number of cholinergic fibers of basal forebrain neurons and 
hippocampal dendritic spines, without affecting the survival of these neurons. 
Conversely, blockade of p75 receptor prevented spine number reduction. These 
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evidences leaded researchers to the conclusion that an incorrect balancing of the 
different isoforms may result in some neuropathological effects. It has been observed 
that BDNF and the tissue plasminogen activator (tPA, a serine protease) both were 
implicated in late-phase long-term potentiation (L-LTP) and long-term memory. In 
vitro conversion of proBDNF to mBDNF by plasmin via the tPAdependent activation 
of plasminogen and mBDNF mediated L-LTP in tPA and plasminogen knock-out 
mices  suggested the existence of a mechanistic link between tPA and BDNF (Pang 
et al., 2004). 
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Figure 4. The synthesis of brain-derived neurotrophic factor (BDNF) from proBDNF. The BDNF gene 
produced precursor protein BDNF (preproBDNF) in the endoplasmic reticulum. ProBDNF binds to 
intracellular sortilin in the Golgi to facilitate proper folding of the mature domain. ProBDNF 
preferentially binds p75NTR receptors. ProBDNF is cleaved by proteases (e.g. plasmin, matrix 
metalloproteinase [MMP]-7) at the synapses and converted to mature BDNF. Mature BDNF 
preferentially binds tropomyosin receptor kinase (Trk) B receptor.  
 
 
In this regard, we decided initially to perform a systematic review and a meta-
analysis of studies measuring serum concentrations of BDNF to elucidate whether or 
not this neurotrophin is abnormally produced in patients with schizophrenia. 
Additionally, we were interested in identifying factors that might contribute to the 
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different findings in literature, as to improve the design of future investigations in this 
field. 
In fact, schizophrenia is a common severe psychiatric disorder which affects 
approximately 1% of the world population. Imaging studies and postmortem analysis 
have clearly shown that schizophrenia is not a mere functional disorder, but rather 
includes several histological abnormalities in various areas of the brain. Today, 
deficits in brain development or a malfunction in the dopaminergic system are 
considered the leading hallmarks of schizophrenia (Fatemi & Folsom, 2009; Howes & 
Kapur, 2009; Iritani, 2007). Although the pathogenesis of schizophrenia remains still 
unresolved, it is now clear that this disorder is the result of a complex interplay 
between inheritable genetic mutations in a large number of genes (a few common 
mutations with a small effect combined with many rare ones with a stronger effect), 
various environmental influences and epigenetic effects (van OS & Kapur, 2009; 
Owen et al., 2009; O‘Donnel et al., 2009; Psychiatric GWAS Consortium [PGC], 
2009; Roth et al., 2009). Over the years, multiple theories have been proposed to 
explain how these factors may generate schizophrenia. The different models 
proposed include principally the neurodevelopmental and the dopaminergic 
hypotheses which have been reviewed elsewhere (Fatemi & Folsom, 2009; Howes & 
Kapur, 2009). These two hypotheses may not necessarily be mutually exclusive as, 
for instance, a local dysfunction in dopaminergic neurotransmission may be the result 
of a failed development. Moreover, a number of studies pointed to the role of 
neurotrophins in the pathogenesis of schizophrenia. Neurotrophins are a small group 
of secreted dimeric proteins that affect the development of the nervous system in all 
vertebrates' species and are involved in the development and maturation of several 
brain networks including the dopaminergic system (Buckley et al. 2007; Shoval & 
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Weizman, 2005; Thome et al. 1998). Brain-Derived Neurotrophic Factor (BDNF) is 
the most widely distributed neurotrophin in the central nervous system (CNS) and is 
known to exert growth and trophic effects able to support many aspects of neuronal 
development including axonal growth and connectivity (Segal et al., 1995), neuronal 
survival and apoptosis (Segal et al., 1997), and formation of dopaminergic-related 
systems. Furthermore, BDNF has a dynamic effect on synaptic organization, 
promoting long-term changes of synaptic transmission (Shen et al., 1997), as well as 
learning and memory processes (Yamada et al., 2002). For these reasons many 
studies investigated the role of BDNF in the pathophysiology of schizophrenia but 
their findings resulted contradictory. For example, some postmortem studies 
conducted on schizophrenia brains showed elevated BDNF levels in the anterior 
cingulate, hippocampus (Takahashi et al., 2000) and cerebral cortex (Durany et al., 
2001), whereas others found decreased BDNF levels in the hippocampus (Durany et 
al., 2001) and prefrontal cortex (Weickert et al., 2003, 2005). Interestingly, in both 
humans and rodents, BDNF is present not only in the brain but also in peripheral 
tissues and especially, in the blood (Pruunsild et al., 2007; Aid et al., 2007). The 
origin of circulating BDNF has been debated as this neurotrophin is produced by 
many different body tissues and epithelia, including smooth muscle cells of blood 
vessels (Donovan et al., 1995). However, it has been demonstrated that radiolabeled 
BDNF injected in the jugular vein or in the brain ventricle readily crosses the blood-
brain barrier in both directions (Pan et al., 1998) and can be taken up by platelets 
that function as storage and release system (Karege et al., 2005). In addition, it has 
been shown that physical exercise induces an increase of serum BDNF levels which 
is contributed by 70% from the brain (Rasmussen et al., 2009). Thus, measurement 
of circulating BDNF is very attractive, because it may provide information on brain 
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functioning and blood samples are largely available and may be drawn non-
invasively from living subjects as frequently as necessary. BDNF can be measured 
using simple enzyme linked immunoadsorbent assays (ELISA) that are commercially 
available and recent methodological studies have pointed out the possibility to obtain 
reliable measures of BDNF in serum preparations with stable values over several 
months of serum storage at  20°C, while in contrast, there is high variability in the 
measures of BDNF in whole blood or plasma because of the presence of release 
from platelets and degradation processes that are active even during storage (Elfving 
et al, 2009; Trajkovska et al., 2007). For these reasons, there is currently a great 
interest to validate the use of serum BDNF as possible biomarker in brain diseases, 
including psychiatric illnesses (for a recent meta-analisis of serum BDNF in 
depression see: Sen et al., 2008). To assess if BDNF can represent a good 
biomarker in schizophrenia, a growing number of studies compared BDNF serum 
levels between patients with schizophrenia and healthy control subjects but 
unfortunately, with controversial results. Indeed, several investigators found a 
significant decrease in serum BDNF concentrations (Carlino et al., 2011; Chen et al., 
2009; Grillo et al., 2007; Ikeda et al., 2008, Jindal et al., 2010; Pirildar et al., 2004; 
Rizos et al., 2008; Shimizu et al., 2002; Tan et al., 2005a, 2005b; Toyooka et al., 
2002; Xiu et al., 2009; Zhang et al., 2007, 2008); while other studies documented 
normal (Shimizu et al., 2003; Jockers-Schrubl et al. 2004; Huang et al. 2006) or even 
increased circulating BDNF (Gama et al., 2007; Reis et al., 2008).  
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3. Methods 
 
3.1 Search strategy 
 
The PUBMED, OVID MEDLINE, PSYCHINFO and EMBASE databases were 
searched using the following medical subject headings (MeSH): ―Brain-Derived 
Neurotrophic Factor‖ OR State of Art of Serum Brain-Derived Neurotrophic Factor in 
Schizophrenia ―BDNF‖ AND ―schizophrenia‖. In addition, all reference lists of the 
selected papers were examined for studies not indexed electronically. The search 
aimed to find all papers published through January 2011.We used the PRISMA 
guidelines to carry out this review (Figure 5). 
 
Figure 5. Flowchart of results of systematic review and meta-analysis search strategy. 
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3.2 Inclusion/exclusion criteria for both the systematic review and meta-
analysis 
 
Studies had to fulfill the following inclusion criteria : 
1. Investigation of serum BNDF levels in patients with schizophrenia and healthy 
comparison subjects. 
2. Mean serum BDNF reported (ng/ml or pg/ml). 
3. Clinical characterization of patients with schizophrenia according to DSM-IV, ICD-
10 or an equivalent system employed as a diagnostic tool. Study samples including 
some schizoaffective or schizophreniform subjects were also considered. 
4. Published in English. 
Exclusion criteria comprised: 
1. Samples including non-schizophrenia psychosis or other schizophrenia spectrum 
disorders. 
2. Plasma BDNF levels were measured. 
3. Publications describing case reports or case series. 
4. Patients or comparison subjects with neurological or medical disorders or 
substance or alcohol abuse. 
5. Comparison subjects screened for psychiatric disorders. 
In addition, in the studies exploring the same subject population or part of it, only the 
publication with the largest sample size was selected. When necessary, study 
Authors were contacted and asked to supply for missing or incomplete information. 
 
 
13 
 
3.3 Data abstraction and quality rating 
 
Each paper was scrutinized by two independent reviewers (D.C. and M.B.) 
separately, and the following data from the article was obtained: age, gender, 
education, age at onset, duration of illness, number of hospitalizations, medications 
used (type, dosage and duration of treatment) and laboratory parameters. Mean 
serum BDNF levels (expressed in ng/ml) and the methods used for statistical 
analyses were also extracted from the article. Furthermore, the reviewers rated the 
quality of each study using a modified version of the quality rating check-list reported 
on Baiano et al. (2007). 
Category 1: subjects 
1. Prospective evaluation of patients, use of specific diagnostic criteria and 
description of demographic data; 
2. Prospective evaluation of healthy control subjects, description of demographic 
data, exclusion of psychiatric and medical illnesses; 
3. Presentation of significant variables (e.g. age, gender, age at onset, duration of 
illness, number of hospitalizations, medications used); 
Category 2: methods for sampling and analysis 
1. Clear description of laboratory technique and measurements, such in a way to be 
reproducible; 
2. Blindness of investigators to experimental setup; 
3. Report of intra and inter-assay reliability; 
Category 3: results and conclusions 
 Use of appropriate statistical tests; 
 Presentation of main results and parameters for statistical significance; 
14 
 
 Consistence of conclusions with the results and discussion of study limits. 
Each item was scored 1, 0.5 or 0 if criteria were completely met, partly met or unmet, 
respectively. This procedure was performed to evaluate the completeness of the 
available publications and not to criticize the investigations per se. 
15 
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Table 1. Methodological aspects of the studies measuring serum BDNF in schizophrenia. 
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3.4 Statistical analysis 
 
The calculations were performed by means of the statistical software package 
STATA 8.0 (StataCorp LP, Texas). Data were analyzed by using a random effects 
model (Metan command), which typically takes into account the between study 
variability, leading to wider confidence intervals than those obtained by a fixed effects 
model. Thus, studies were weighted for the inverse variance, obtaining the 
DerSimonian-Laird‘s effect size (Deeks et al., 2001). Heterogeneity between studies 
was explored using the Q-test. Since we hypothesized a statistically significant 
heterogeneity, a meta-regression analysis was planned to assess the effects of 
selected factors (i.e.: gender distribution, ethnicity, ELISA kit used and average age) 
on results between studies (Metareg command). Publication bias was assessed by 
Egger‘s tests (Egger et al., 1997) (Metabias command). All p values were two sided 
and the cutoff for statistical significance was 0.05. 
 
4. Results 
 
4.1 Systematic review 
 
A total of 334 references were obtained. All the studies found in PUBMED database 
overlapped with those retrieved using OVID MEDLINE and PSYCHINFO databases. 
A total of 1036 references were identified. All the studies found in PUBMED database 
overlapped with those retrieved using OVID MEDLINE, EMBASE, PSYCHINFO lists. 
Most of them (322) did not meet the inclusion criteria, most analyzing val66met 
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BDNF polymorphism, mRNA expression or post-mortem studies. Thus, 17 were 
finally considered but 16 were actually included in the systematic review (Carlino et 
al., 2011; Chen et al., 2009; Gama et al., 2007; Grillo et al., 2007; Huang et al., 2006; 
Ikeda et al., 2008; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Pirildar et al., 
2004; Reis et al., 2008; Rizos et al., 2008; Shimizu et al., 2003; Tan et al., 2005a; 
Toyooka et al., 2002; Xiu et al., 2009; Zhang et al., 2008). Indeed, as per Authors 
suggestion, we excluded the study by Zhang et al. (2007) (124 patients and 50 
controls) since the patients‘ sample consistently overlapped with that of the study 
published by Zhang and co-workers in the 2008 (196 patients and 50 controls). 
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Table 2. Clinical characteristics of studies included in the meta-analysis. International HapMap 
Project: YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo; CHB: Han Chinese in Beijing, China; 
CEU: CEPH (Utah residents with ancestry from Northern and Western Europe). 
 
 
4.1.1 Findings 
 
Most of the studies (12/16) measuring serum BDNF documented lower 
concentrations of this neurothropin in patients with schizophrenia (Carlino et al., 
2011; Chen et al., 2009; Grillo et al., 2007; Ikeda et al., 2008; Jindal et al., 2010; 
Jockers-Schrübl et al., 2004; Pirildar et al., 2004; Rizos et al., 2008; Tan et al., 
2005a; Toyooka et al., 2002; Xiu et al., 2009; Zhang et al., 2008); however, in other 
studies, BDNF concentrations were either increased (Gama et al., 2007; Reis et al., 
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2008); or normal (Huang et al., 2006; Shimizu et al., 2003) (Table 1). Five out of the 
16 researches investigated gender effects, demonstrating either significantly lower 
(Xiu et al., 2009) or higher serum BDNF levels in males suffering from schizophrenia 
(Gama et al., 2007). Conversely, no gender effect emerged in Carlino et al., (2011), 
Huang et al. (2006) and Rizos et al. (2008) and in all healthy control subjects. 
 
4.1.2 Clinical features of patients 
 
15/16 studies reported on the mean age of the patients with schizophrenia (mean: 
37.22 9.48 SD years; range: 22.4-52.3). Nine studies provided data for age of onset 
of schizophrenia (mean: 25.70 4.86 SD years; range: 19.93-33.8) and 13 for length 
of illness (mean: 180.13 127.65 SD months; range 8.8-388.8). Six out of 16 papers 
reported on the mean dosage of antipsychotic medications, expressed as 
chlorpromazine equivalents (mean: 581.12 219.90 SD; range:330.4-936.6). In one 
paper (Zhang et al., 2008), data for other psychopharmacological treatment (lithium, 
valproic acid) were included, but there were no details about the role of these drugs 
on serum BDNF levels. Only Jockers- Schrübl et al. (2004) evaluated the role of 
substance abuse (cannabis) in serum BDNF levels: the Authors found significantly 
elevated BDNF serum concentrations (by up to 34%) in patients with chronic 
cannabis abuse or multiple substance abuse prior to disease onset. Drug-naïve 
schizophrenic patients without cannabis consumption showed similar results to 
normal controls and cannabis controls without schizophrenia. In relation to the source 
of recruitment, 6/16 studies included only inpatients (Chen et al., 2009; Reis et al., 
2008; Rizos et al., 2008; Tan et al., 2005a; Xiu et al., 2009; Zhang et al., 2008), 1/16 
included only outpatients (Gama et al., 2007), 3/16 considered both in-patients and 
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out-patients (Carlino et al., 2011; Huang et al., 2006; Ikeda et al., 2008) and 6/16 
publications did not provide data (Grillo et al., 2007; Jindal et al., 2010; Jockers-
Schrübl et al., 2004; Pirildar et al., 2004; Shimizu et al., 2003; Toyooka et al., 2002). 
In our research, we found that Japanese subjects were investigated in three studies 
(Ikeda et al., 2008; Shimizu et al., 2003; Toyooka et al., 2002), Caucasians in 
another four studies (Carlino et al., 2011; Jockers-Schrübl et al., 2004; Pirildar et al., 
2004, Rizos et al., 2008) and Asians in five studies (Chen et al., 2009; Huang et al., 
2006; Tan et al., 2005a, Xiu et al., 2009, Zhang et al., 2008). In four studies, ethnicity 
was unspecified (Gama et al., 2007; Grillo et al., 2007, Reis et al., 2008; Jindal et al., 
2010). Six studies reported no diagnostic subtypes of schizophrenia (Ikeda et al., 
2008; Gama et al., 2007; Jockers- Schrübl et al., 2004; Pirildar et al., 2004;Reis et 
al., 2008; Rizos et al., 2008; Toyooka et al., 2002) while in seven studies it was 
assessed the differences in serum BDNF levels among diagnostic subtypes (Chen et 
al., 2009; Grillo et al., 2007; Huang et al., 2006; Shimizu et al., 2003; Tan et al., 
2005a; Xiu et al., 2009; Zhang et al., 2008). Different forms of schizophrenia had no 
association with BDNF serum levels in 5 papers (Grillo et al., 2007, Shimizu et al., 
2003; Tan et al., 2005a; Xiu et al., 2009; Zhang et al., 2008), while Chen et al. (2009) 
showed significantly higher BDNF levels in paranoid (10.4 ± 4.3 ng/ml) compared to 
undifferentiated (8.0 ± 3.9 ng/ml) and other combined subtypes (7.5± 4.1 ng/ml). 
Huang et al. (2006) showed that patients with catatonic schizophrenia had lower 
serum BDNF protein levels than patients with paranoid schizophrenia and residual 
schizophrenia. In a second step, phase of illness and use of antipsychotic drugs were 
considered. We found that four studies enrolled only drug-naïve first-episode patients 
(Chen et al., 2009; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Rizos et al., 
2008), eight studies recruited only chronic, medicated patients (Carlino et al., 2011; 
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Gama et al., 2007; Ikeda et al., 2008; Reis et al, 2008; Tan et al., 2005a; Toyooka et 
al., 2002; Xiu et al., 2009; Zhang et al., 2008) and two studies included medicated 
patients with unclear phase of illness (Grillo et al., 2007; Huang et al., 2006). Notably, 
the study by Pirildar et al. (2004) and Shimizu et al. (2003) investigated both 
chronically antipsychotic-treated and drug-naïve patients; in particular, in Pirildar et 
al. (2004) some first episode medicated subjects were included. All the 16 studies 
excluded patients with a history of neurological disease, physical illness, and alcohol 
or substance abuse. Clinical data are summarized in Table 2. 
 
4.1.3 Serum BDNF concentrations and laboratory procedures 
 
Among studies, laboratory procedures were comparable with some minor variations. 
Sera were centrifuged to eliminate the blood clot with a mild centrifugation at 2000, 
3000 or 3500 rpm for 5-15min at room temperature or 15°C); then, they were stored 
frozen at -70/ 80°C until used. Serum BDNF concentrations were measured using 
sandwich ELISA assays (see Table 1 for full detail). Finally, all the studies except 
one (Gama et al., 2007) reported clearly on mean BDNF concentrations. Specifically, 
mean serum BDNF values were 14.43 10.24 SD ng/ml (range: 0.098-37.1) for 
patients and 17.99 13.41 SD ng/ml, (range: 0.12-52.2) for healthy blood donors. 
 
4.1.4 Study quality 
 
The mean total quality scores for the reports were 7.63±1.17 SD (min.:5.5; max.: 9). 
We correlated total and partial quality scores of studies on serum BDNF with the year 
of publication, which was significantly positively correlated to total quality score 
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(r=0.53) and State of Art of Serum Brain-Derived Neurotrophic Factor in 
Schizophrenia study methodology score (Category 2) (r=0.59) but not to study design 
score (Category 1) (r=  0.20) or study consistency score (Category 3) (r=0.27). 
 
4.1.5 Meta-analysis 
 
Fifteen out of the 16 publications considered for the systematic review were used for 
the meta-analysis (Carlino et al., 2011; Chen et al., 2009; Grillo et al., 2007; Huang et 
al., 2006; Ikeda et al., 2008; Jindal et al., 2010; Jockers-Schrübl et al., 2004; Pirildar 
et al., 2004; Reis et al., 2008; Rizos et al., 2008; Shimizu et al., 2003; Tan et al., 
2005a; Toyooka et al., 2002; Xiu et al., 2009; Zhang et al., 2008). The study by 
Gama et al., (2007) was eliminated, as it was the only one to report serum BDNF in 
pg/μg of total protein while in all other studies serum BDNF concentration was given 
in ng or pg/ml serum and therefore, no comparison between the Gama‘s and the 
other studies was possible. Since the studies by Shimizu et al., (2003) and Pirildar et 
al., (2004) reported on separate data for both medicated and unmedicated patients, 
we performed calculations considering patients‘ subgroups as follows: Shimizu et al., 
2003 part I and Pirildar et al., 2004 part I = medicated patients; Shimizu et al., 2003 
part II and Pirildar et al., 2004 part II = unmedicated patients. Therefore, we carried 
out calculations on 17 samples of patients. Raw total serum BDNF levels (ng/ml) 
were used to calculate the related effect sizes. The overall estimate of SMD 
(standardized mean differences) in serum BDNF levels between patients with 
schizophrenia and healthy controls was significant (z=4.14; p<0.001) but 
considerable heterogeneity emerged from publications (Q=139.15; d.f.=16; p<0.001; 
τ²= 0.2826) (Figure 2). Therefore, we regressed the SMD against potential sources of 
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heterogeneity (i.e.: gender, age, ethnicity and ELISA kit used). This analysis 
demonstrated a significant association of BDNF levels with all these variables (age: 
z=15.28; gender: z=10.92 for males; z=4.60 for females; ethnicity: Z=9.37 and ELISA 
kit: z=8.55; p<0.001). Moreover, to determine if this systematic review and meta-
analyses was subjected to publication bias (i.e. the presence of asymmetrical 
collection of data due to the missing of studies reporting negative results, or to the 
tendency of small studies to show greater effects than larger studies), we carried out 
the Egger‘s weighted regression and evidence of significant publication bias was 
found (p<0.001). Subsequently, the eleven studies investigating chronic, medicated 
patients with schizophrenia were considered (Carlino et al., 2011; Grillo et al., 2007; 
Huang et al., 2006; Ikeda et al., 2008; Pirildar et al., 2004 part I; Reis et al, 2008; 
Shimizu et al., 2003 part I; Tan et al., 2005a; Toyooka et al., 2002; Xiu et al., 2009; 
Zhang et al., 2008). Significant heterogeneity was found (Q=120.85, d.f=10, p<0.001, 
τ²=0.3545) and patients and healthy control subjects differed for serum BDNF levels, 
as demonstrated by the SMD test (z=2.69; p=0.007) (Figure 3). The meta regression 
analysis showed that age (z=13.89), gender (z=11.09 for males; z=7.36 for females), 
ethnicity (z=6.76), type of ELISA kit (z=6.67), chlorpromazine equivalents‘ medication 
dosage (z=5.97) and duration of illness (z=7.03) may all explain heterogeneity 
(p<0.001). Similar results were obtained by meta-analyzing the six studies including 
first episode unmedicated patients (Chen et al., 2009; Jindal et al., 2010; Pirildar et 
al., 2004; Rizos et al., 2008; Shimizu et al., 2003 part II) (Figure 4). Indeed, we found 
that both the Q test for heterogeneity (Q=18.30; d.f =5; p=0.003; τ²=0.1595) and 
Dersimonian and Laird pooled effect size (z=3.06, p=0.002) were significant. As 
previously demonstrated, heterogeneity may be due to age (z=15.33), gender 
(z=4.55 for males; z=4.84 for females), ethnicity (z=5.47), type of ELISA kit (z=4.45). 
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Figure. 6. Forrest plot depicting the meta-analysis of serum BDNF levels in patients with 
schizophrenia. 
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Figure 7. Forrest plot presenting the meta-analysis of serum BDNF in chronic medicated patients 
with schizophrenia. 
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Figure 8. Forrest plot presenting the meta-analysis of serum BDNF in unmedicated patients with 
schizophrenia. 
 
 
5. Conclusions of meta-analysis. 
 
Our systematic review and meta-analysis showed that lower serum BDNF levels 
were detected in patients with schizophrenia in comparison to healthy controls in 
most even if not in all studies. Interestingly, reduced serum BDNF levels were found 
both in drug-naïve first episode and chronic medicated schizophrenia patients, as 
also found in studies investigating plasma BDNF concentrations (Buckely et al., 
2007; Palomino et al., 2006; Tan et al., 2005b). These findings show that reduced 
serum BDNF levels are associated with schizophrenia but also suggest that serum 
BDNF is not a crucial biological marker of the clinical state in schizophrenia or a 
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marker of antipsychotic medication efficacy, in agreement with a recent meta-
analysis (Green et al., 2010). The serum BDNF concentration in healthy populations, 
varied from a minimum of 0.17 ng/ml (Grillo et al., 2007) to a maximum of 52.2 ng/ml 
(Ikeda et al., 2003), the mean value among the thirteen paper analysed was 16.2 
ng/ml (SD=14.59). Although we observed variability between studies using the same 
commercial ELISA, differences in serum BDNF concentration appeared mainly due 
to the different kit used. For example the three studies which used the kit purchased 
from BanDing Biomed reported values of serum BDNF in Chinese healthy donors of 
11.9 + 2.3 ng/ml (Xiu et al., 2009); 9.4 + 4.4 ng/ml (Zhang et al., 2008); 9.1 + 4.3 
ng/ml (Tan et al., 2005) while higher levels of serum BDNF were detected with the kit 
from Promega in healthy donors from Japan, 28.5 + 9.1 ng/ml (Shimizu et al., 2003); 
Turkey 26.8 + 9.3 ng/ml (Pirildar et al., 2004) and Taiwan 14.17 + 6.9 ng/ml (Huang 
et al., 2006). Finally, two studies using the R&D System ELISA assay showed very 
distant results because Rizos et al. (2008) detected 30.0 + 8.4 ng/ml of serum BDNF 
in healthy controls from Greece while Reis et al., (2008) in Brazil, found 4.31 + 2.1 
ng/ml. Two other studies from Brazil also showed particularly low levels using the 
assay from another company (Chemicon), i.e. 0.19 + 0.1 ng/ml (Gama et al., 2007) 
and 0.17 + 0.0 ng/ml (Grillo et al., 2007). It is possible that this finding might reflect 
reduced amounts of serum BDNF in the Brazilian population. Another interpretation 
suggests a very low sensitivity of the ELISA kit from Chemicon. In conclusion, the 
most likely range of concentrations of serum BDNF in the World healthy population is 
9-30 ng/ml with some possible specific regional variations. However, the great 
heterogeneity between studies and the presence of a publication bias may limit the 
interpretation of these results. Firstly, the phenotypic complexity, together with the 
multifarious nature of the so-called ―schizophrenic psychoses‖, limits our ability to 
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form a simple and logical, biologically-based hypothesis for the disease group. 
Secondly, all studies used ELISA assays that have different sensitivity and cannot 
distinguish between the three different protein forms of BDNF consisting in the 
precursor pro-BDNF (of 32 KDA) and its two proteolytic products mature BDNF 
(mBDNF of 14KDa) and truncated BDNF (truncBDNF of 28 KDa). Since pro-BDNF 
and mBDNF elicit opposing actions on synaptic plasticity and cell survival, their 
distinction could be essential to determine the role of BDNF in specific aspects of 
schizophrenia‘s neurobiology. 
 
5.1 The role of proBDNF in patients with schizophrenia 
 
BDNF is initially synthesized as a 32 KDa precursor protein (prepro-BDNF) in 
endoplasmic reticulum, and then processed into two isoforms (as the truncated-
BDNF 28 KDa and mature 14 kDa BDNF) by two different proteolitic cleavages. 
Mature BDNF (mBDNF) is generated either intracellularly in the trans-Golgi by furin 
(Mowla et al., 2001, Matsumoto et al., 2008), or extracellularly by plasmin or 
matrixmetalloprotease-7 (Lee et al., 2001, Yang et al. 2009; Nagappan et al., 2009). 
Truncated-BDNF is cleaved by the Membrane Bound Transcription Factor Site-1 
protease (MBTFS-1), also identified as Subtilisin/kexin isozyme 1 (Seidah et al., 
1999). This isoform is not further processed into mBDNF and its function has not 
been elucidated yet. According to the ―Ying and Yang‖ hypothesis (Lu et al., 2005), 
both mBDNF and proBDNF have particular neurobiological properties. In particular, 
proBDNF regulate neuronal survival (Teng et al., 2005; Koshimizu et al., 2009; Woo 
et al., 2005) and boosts synaptic pruning whereas mBDNF improves the 
differentiation of new neurons. Also, the conversion of proBDNF into mBDNF seems 
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to be decisive for signal transmission and synaptic plasticity. Indeed, mBDNF and the 
Tissue Plasminogen Activator (TPA) but not proBDNF are essential in late-phase 
long-term potentiation (L-LTP) and long-term memory (Pang et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The ying-yang hypothesis 
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Figure 10. The ying-yang hypothesis and its relationship with long-term potentiation and long-term 
depression  
 
These results underscore that a wrong matching of the proBDNF/mBDNF ratio may 
alter neuroplastic mechanisms, corresponding to the neurobiological substrate of 
impaired cognitive performance. An increasing number of postmortem researches 
have been carried out to measure the expression of proBDNF and mBDNF isoforms 
in animal models and in healthy human volunteers or subjects affected by 
neuropsychiatric disorders. Reduced mBDNF levels were found in three studies 
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(Karege et al., 2005; Weickert et al., 2003; Wong et al., 2010), particularly in the 
dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia compared to 
healthy controls. Weickert et al. (2003) found that mBDNF protein levels were not 
associated with post-mortem interval (PMI), tissue pH, age, or storage time of the 
serum. There were no significant main influences of gender or brain hemisphere, nor 
significant correlations between diagnosis and gender or diagnosis and brain 
hemisphere. On the other hand, Chen et al. (2001) showed that there was no 
significant variation for mBDNF among patients with schizophrenia and those with a 
diagnosis of affective disorders (unipolar and bipolar disorders) and Dunham et al., 
(2009) detected no difference for preproBDNF (35KDa) between patients with 
schizophrenia and those with unipolar depression and bipolar disorder. In contrast, 
Wong et al. (2010) found reduced truncated BDNF and preproBDNF proteins in the 
DLPFC of patients with schizophrenia, even if the reduction in preproBDNF protein 
did not achieve statistical significance. In a previous study (Carlino et al., 2011), we 
provided evidence of variation in serum levels of different BDNF isoforms in patients 
with chronic schizophrenia.  
 
5.2 The role of ethnic differences in serum BDNF levels in patients with 
schizophrenia 
 
An element of heterogeneity that emerges from this meta-analysis is represented by 
the ethnic differences amongst the samples. In this context it is of great interest to 
note that there are divergent findings of the positive or negative associations 
between BDNF val66met polymorphism and schizophrenia, especially in Caucasian 
and Asian participants. These differences may partially explain the differences in 
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serum BDDNF levels among papers. Studies in in vitro and in animal models have 
shown that Met allele alters both sorting and secretion of proBDNF, such that less 
regulated (activity dependent) secretion is likely to occur in carriers of at least one 
Met allele. Several genetic associational studies have shown that SNPs in BDNF are 
associated with schizophrenia (Nanko et al., 2003; Szekeres et al., 2003), and a 
meta-analysis study also illustrated an association between C270T and 
schizophrenia (Zintzaras, 2007), but not between Val66Met and schizophrenia 
(Kanazawa et al., 2007; Naoe et al., 2007; Xu et al., 2007; Zintzaras, 2007). Great 
differences in the allelic frequencies for the BDNF Val66Met polymorphism between 
populations of different ethnic origins have been reported in public databases 
(http://www.hapmap.org) for the same populations (Tables 3 and 4). In Caucasian 
subjects, the frequency of the Met allele is 25–32%, whereas in Asian peoples the 
Met allele is more frequent, around 40–50% (Pivac et al., 2009; Verhagen et al., 
2010). These variations among different ethnic groups in the allelic frequencies of the 
BDNF polymorphism may be caused by either the natural selection of an 
advantageous allele by unknown environmental issues or through a founder effect. 
However, we advise prudence in the analysis of these facts, also because despite 
this obvious difference in outcomes of schizophrenia across ethnicities, cross-cultural 
research in psychiatry focuses on similarities rather than differences. For example, 
subtypes of schizophrenia may have different prevalence across countries: in the 
International Pilot Study of Schizophrenia (1973) and the Determinants of Outcome 
of Severe Mental Disorders study (1992), catatonia was identified in 10% of cases in 
developing countries respect to less than 1% in developed countries. Hebephrenia 
was found in 13% of cases in developed countries and 4% in developing countries. 
Currently, we have not sufficient data about the role of diagnostic subtypes and 
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serum BDNF levels or BDNF polymorphisms. Another diagnostic caveats regards the 
Caucasian studies that often investigated not only patients with schizophrenia, but 
also subjects with schizophrenia spectrum disorders such as schizophreniform 
disorder or schizoaffective disorder, while Asian and other studies investigated only 
patients with schizophrenia. This difference in methodology might also have 
contributed to the inconsistent findings between the Caucasian and the Asian 
studies. The substantial variation in the Val66Met frequencies between Asian and 
Caucasian samples indicates that ethnicity may be of importance in the issue, 
because if the association among Caucasians reflects linkage disequilibrium with 
another gene variant, the extent of linkage may vary between populations. A recent 
study focused on the complex microsatellite polymorphism BDNF-LCPR located ~1.0 
kbp upstream of the translation initiation site of BDNF (Okada et al., 2006); this 
polymorphism contained 23 novel allelic variants, including four major alleles (A1–
A4). Kawashima et al. (2009) consider that if BDNF is indeed associated with 
schizophrenia, the A1 allele in BDNF LCPR would be a hopefully useful marker in the 
Japanese population. Also, we must not forget the interchange between genetic and 
environmental issues, that may essentially vary for men and women. In this regard, it 
would be interesting to evalute if gender-related epistatic effects pertaining to the 
Val66Met polymorphism subsist. Literature data showed that gender differences in 
schizophrenia reproduce divergences in neurodevelopmental mechanisms and social 
influences on illness risk and course. Men have poorer premorbid functioning and 
have worse negative and less depressive manifestations than women. Substance 
abuse is more frequent in male. Results of gender variations in brain morphology 
(e.g. hippocampal volume) are conflicting but refer to matter of sexual dimorphism, 
meaning that the same elements are significant to explain sex disparities in both 
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normal neurodevelopment and those in relationship with schizophrenia. Another 
factor to consider is the epigenetic influence. “Epigenetic‖ refers to the covalent 
modifications of chromatin. Epigenetic machinery not only is responsible for lasting 
differences in gene activity in the CNS but also controls gene expression necessary 
for cognition. Thus, the likelihood of an epigenetic involvement in schizophrenia is an 
interesting hypothesis. In fact, epidemiological studies have identified several 
environmental risk factors for schizophrenia, counting marijuana consumption and 
obstetric complications. A recent study by Nicodemus and colleagues (2008) showed 
a significant association between four candidate genes for schizophrenia which are 
likely to have a role in hypoxic situations, including BDNF detecting significant 
evidence for gene x environment interaction in schizophrenic patients with or without 
obstetric complications. Recently, several studies underline that DNA methylation 
contributing to ongoing regulation of BDNF transcription in the CNS to control 
synaptic plasticity and memory mechanism (for e review, see Roth et al., 2009a). In 
addition, BDNF DNA methylation has also been found to play a part in altered gene 
expression in response to environmental pressure, such as social experiences (Roth 
et al., 2009). Indeed, stressful social experiences early in life have long-lasting 
consequences such as increased anxiety, drug seeking behavior, cognitive 
impairment, and altered affiliative behaviours (Branchi et al., 2004; Fumagalli et al., 
2007; Lippmann et al., 2007). Finally, it was recently revealed that social experiences 
early during the first postnatal week generate lasting changes in DNA methylation in 
BDNF gene in relationship with reduction of BDNF gene expression in the adult 
prefrontal cortex (Roth et al., 2009b). Overall, the available data suggest that DNA 
methylation may indeed be an epigenetic mechanism that contributes to the aberrant 
regulation of genes associated with schizophrenia. The hard work to recognize 
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vulnerability genes for multifactorial disorders such as schizophrenia, has inspired 
the development of alternative methodologies. Since genetic heterogeneity has been 
a major dilemma in complex disorders, investigators have attempted to increase 
homogeneity in their samples. Recently, alternative phenotypic definitions have been 
defined that might be more closely linked to biological pathway (endophenotypes), for 
example sensory gating deficits or working memory dysfunction (Gottesman and 
Gould, 2003). Another advance to decrease basic genetic complexity is the utilization 
of genetic isolates. Isolated populations originated from a small number of founder 
couples. Throughout history, many populations, counting isolated as well as outbred 
populations, undergo alternating era of adversities (e.g. war, epidemics, or famine) 
with period characterized by rapid growth of the population. Due to increased 
inbreeding and genetic drift in isolates, certain alleles will be present more frequently 
in the population, while others are lost, increasing genetic homogeneity. Additionally, 
due to geographic, cultural, or religious barriers, isolated populations did not 
experience a large degree of admixture with adjacent peoples for many generations, 
ensuing in a relatively small gene pool (―founder effect‖). So the recognition of a gene 
or allele that clinically and/or genetically is not as important in outbred populations as 
in isolated populations might untangle molecular pathways and find out new 
candidate genes, which might have a higher involvement on illness risk in general. 
Several studies highlight susceptibility loci for schizophrenia in isolated populations 
(Venken et al., 2007). 
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Figure 3. YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo, Japan; CHB: Han Chinese in 
Beijing, China; CEU: CEPH (Utah residents with ancestry from northern and western Europe). G/G = 
Met/Met; A/G =Val/Met; A/A = Val/Val. 
Allele 
 
 
Figure 4. YRI: Yoruba in Ibadan, Nigeria; JPT: Japanese in Tokyo, Japan; CHB: Han Chinese in 
Beijing, China; CEU: CEPH (Utah residents with ancestry from northern and western Europe). 
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6. Is altered BDNF proteolytic processing a general feature in patients with 
cognitive impairment? 
 
6.1 Role of pro/matBDNF in animal models of learning and memory 
 
The molecular mechanisms supporting the long-term fear memory (Rodrigues SM, et 
al., 2004; Costa-Mattioli M, et al., 2007; LaLumiere RT et al., 2005) are very similar to 
those involved in the memory formation in neuronal circuits, L-LTP (Raymond, 2007). 
Barnes et al. (2008) showed that reduced proteolysis of proBDNF in the 
hippocampus is fundamental to regulate protein synthesis-dependent extinction of 
contextual fear memory (CFM). Importantly, increasing endogenous proBDNF and 
reducing mBDNF levels in the CA1 supported extinction. On the contrary, the 
formation of CFM was associated with increased proteolytic processing of proBDNF. 
Therefore, the processing of BDNF was associated with the acquisition and updating 
of information related to salient stimuli ,mediating changes in behaviour. Thus, BDNF 
regulates the acquisition, consolidation and extinction of fear memory, but not 
reconsolidation. Indeed, the tPA mediated proteolysis of proBDNF facilitates new 
learning but be in opposition to the extinction of strengthened memories. Several 
studies sustained that peripheral administration of lipopolysaccharide (LPS) injuring 
the LTP (Vereker et al., 2000; Hauss-Wegrzyniak et al., 2002; Kelly et al., 2003a,b; 
Bany et al., 2005) and other types of hippocampal-based learning (Shaw et al., 
2001). Moreover, it was hypothesized that peripheral LPS somministration caused 
memory deficit in adult rats after perinatal programming (Gayle et al., 2004; Bilbo et 
al., 2005). The intraperitoneal administration of a single, high dose of endotoxin 
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decreased proBDNF- and BDNF protein levels at synaptic sites in adult mouse 
brains. These changes were associated with a reduction in BDNF-, CRH- as well as 
POMC (pro-opiomelanocortin) mRNA levels (Schnydrig et al., 2007). Since it was 
known that prenatal exposure to opiates,  favored abnormal cognitive performance, 
Schrott et al. (2008) examined whether continuous exposure to the opiate l-α-
acetylmethadol (LAAM) affected BDNF biosynthesis, as well as acquisition or 
retention of a complex learning task (i.e.the eight-arm radial maze) Rats prenatally 
exposed to LAAM had poorer cognitive performance than prenatal water-treated 
controls, although they were able to acquire the task by the end of training and there 
were no differences between the groups on retention 24 hr after testing. Also, 
proBDNF precursor protein was significantly decreased in the synaptic fraction of 
trained prenatal LAAM-treated rats compared to prenatal water-treated trained 
controls. In untrained rats, prenatal treatment did not affect any of the measures.  
Silhol et al. (2007) studied BDNF and proBDNF hippocamapl levels  in young (2-
month-old) and aged (24-month-old) Wistar rats, before and after learning task 
training.  Spatial memory was assessed by a water-maze procedure linking visible 
and invisible platform location learning. Under basal conditions, BDNF levels 
measured using ELISA assay was higher in the hippocampus of aged rates versus 
those of young rats. As expected, after the learning task the BDNF content was 
significantly increased in young rats but not in the same rats. Nevertheless, since it 
has been previously reported that the ELISA assay antibody recognizes other BDNF 
containing molecules (Fayard et al., 2005; Silhol et al., 2005), the BDNF content was 
analyzed more specifically by Western blot. Results substantially replicated those 
obtained using the ELISA assay; moreover, proBDNF levels were significantly 
increased after training both in young and aged rats. The same research group 
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(Silhol et al., 2008) determined the BDNF content by ELISA assay in Lou/C rats, an 
inbred strain of Wistar origin, which is a known animal model of successful aging with 
a longer lifespan and conserved memory abilities than other rat strains. The Authors 
showed that the hippocampus of young Lou/C rats had two-fold higher BDNF 
concentrations than that of young Wistar rats; additionally both young and aged 
Lou/C rats had higher amounts of BDNF and proBDNF contents. In aged Lou/C rats 
the decrease of hippocampal BDNF t detected by ELISA assay was associated with 
reduced proBDNF content,  as BDNF levels remained unchanged in young and aged 
rats. In contrast, in aged Wistar rats the increase of BDNF content measured with 
ELISA assay was due to increased levels of the two peptides, i.e., BDNF (14-kDa 
band) and proBDNF (28-kDa band). Differences were noted in the dentate gyrus and 
CA1 layers, and aged Lou/C rats had less proBDNF-labeled cells in the superior 
blade of the dentate gyrus than young Lou/C rats. Conversely, aged Wistar rats had 
more labeled cells than young Wistar rats in this region. In the dentate gyrus inferior 
blade, no significant differences were observed between the two groups. A slight but 
significant difference was noted in the CA1 layer of aged Wistar rats that presented 
more labeled cells than young rats. It is known that the tolloid/bone morphogenetic 
protein-1 (BMP-1) family of metalloproteinases is involved in synaptic plasticity in 
human adults. To this date,  Keifer et al. (2009) examined the role of a reptilian 
orthologue of the tolloid gene family (turtle tolloid-like gene or tTLL) in an in vitro 
model of eyeblink classical conditioning using an isolated brain stem preparation. 
Analysis by real-time RT-PCR showed that an extracellularly secreted form of 
tTLL(tTLLs), was momentarily expressed in the early phases of conditioning; 
furthermore, it was observed that tTLLs cleaved proBDNF into mBDNF in and 
expression of recombinant tTLLs protein induced mBDNF expression. mBDNF is 
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modestly expressed in cultures treated with anti-tTLL siRNA. Zheng et al., 2010 
found that application of oligomeric Amyloid-β (Aβ)  in another in vitro model of 
classical conditioning impaired acquisition of conditioning. This effect was associated 
with inhibition of mBDNF protein expression, suppressed phosphorylation of key 
signal transduction elements, and reduced AMPA receptor synaptic delivery. The 
oligomeric Aβ appeared to affect the normal role of a learning-induced  tTLLs, which  
cleaves proBDNF to mature BDNF. Therefore, the Aβ-mediated BDNF reduction may 
be a secondary effect of its ability to move proteolytic processing away from its 
normal substrates during learning. 
 
6.2 Altered processing of BDNF in patients with cognitive impairment  
 
Peng et al. (2005) found that the amount of proBDNF (36 KDa) decreased 21 and 
30% in mild cognitive impairment (MCI) and Alzheimer‘s Disease (AD) groups, 
respectively, as compared with healthy subjects, consistent with their previous results 
of a 40% decrease in end-stage AD (Michalski et al., 2003).  mBDNF was reduced 
34 and 62% in MCI and AD groups, respectively (Peng et al., 2005). Thus, the 
decrease of mature BDNF and proBDNF precedes the decline in choline 
acetyltransferase activity, which typically occurs later in AD. Both proBDNF and 
mBDNF levels were positively correlated with cognitive measures, as the Global 
Cognitive Score and Mini Mental State Examination score.  Weickert et al. (2003) 
detected significantly reduced levels of  mBDNF (by over 40%) in the dorsolateral 
prefrontal cortex (DLPFC) inpatients with schizophrenia compared to normal controls. 
BDNF protein levels within the DLPFC did not correlate with the average daily dose 
of neuroleptics, the dose of neuroleptics most recently taken, the lifetime neuroleptic 
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exposure estimate, age of onset, and illness duration. These findings were replicated 
in the study carried out by Wong  et al. (2010), with a 23% reduction in mBDNF 
immunoreactive levels in schizophrenic subjects. The expression of the 32 kDa 
preproBDNF and 28 kDa proBDNF protein was reduced by 14% and 10.4% in 
schizophrenics versus  to controls respectively, although only the proBDNF protein 
reached the statistical significance. No significant correlation was found between  
mBDNF and age. Conversely, the Authors observed a significant positive correlation 
between proBDNF and age. Finally, BDNF protein expression in the DLPFC was not 
significantly correlated with duration of illness or any estimated measure of 
antipsychotic exposure. In support of these findings, Karege et al. (2005) reported 
that  mBDNF was reduced in the DLPFC of a mixed group of patients including some 
patients with schizophrenia. In opposition while in the study of Duhnam et al. (2009) 
although in schizophrenia mean proBDNF (35 KDa) densities were lower than 
controls in most subregions, they did not reach significance.  
 
44 
 
Table  5*. Characteristics of each preclinical study who investigated precursor forms of BDNF. 
Authors  Paradigm 
Subregions 
dissected/neuronal 
culture 
Animal model 
Antibodies/ 
chemicals 
Principal findings 
Schnydrig et 
al., 2007 
Effects of a single i.p. 
injection of LPS on 
proBDNF-/BDNF protein 
expression 
Crude synaptosomal 
preparations 
C57BL/6J mice 
Santa Cruz 
Biotechnology 
Transient reductions in synaptosomal proBDNF- and BDNF protein expression.  
BDNF-, CRH- and POMC mRNA levels are also significantly reduced. 
Silhol 
et al., 2007 
Spatial learning in the 
water-maze 
DG, CA1, CA2, CA3 
Wistar young (2-month-old), 
aged (24-month-old) adult 
male rats 
Santa Cruz 
Biotechnology 
Training increased the proBDNF content in both young and aged rats which can 
probably be processed in BDNF. 
Silhol 
et al., 2008 
 DG, CA1, CA2, CA3 
Young (2 month-old) and 
aged Lou/C vs matched 
Wistar (23–25 months old) 
rats 
Santa Cruz 
Biotechnology 
Young and aged Lou/C rats had higher amounts of BDNF and proBDNF content than 
Wistar rats. 
proBDNF content was reduced in aged Lou/C rats and increased in aged Wistar rats. 
Barnes et al., 
2008 
Fear conditioning  CA1 Adult male Lister hooded rats Chemicon  
Acquisition and extinction of CFM depend on the increased and decreased 
proteolysis of proBDNF in the hippocampus, respectively. 
Reconsolidation of CFM is not correlated with altered proBDNF cleavage. 
Keifer et al., 
2009 
Eyeblink classical 
conditioning 
The pons with the 
cerebellar circuitry 
removed 
Pseudemys scripta elegans 
Santa Cruz 
Biotechnology 
Expression of an extracellularly secreted tolloid-like metalloproteinase is regulated in 
the early stages of classical conditioning and functions in the conversion of proBDNF 
to mBDNF. 
Zheng et al., 
2010 
Classical conditioning 
The pons with the 
cerebellar circuitry 
removed 
Pseudemys scripta elegans 
Santa Cruz 
Biotechnology 
An Aβ-induced reduction in BDNF, due to interference in the proteolytic conversion of 
proBDNF to mBDNF. 
 
*HFS=High Frequency Stimulation, LFS=Low Frequency Stimulationm, Aβ=Amiloid-Β, NPV=Negative Predictive Value; I-TBS: theta burst stimulation, IOP:intraocular pressure, HFS: high frequency 
stimulation, LES: low frequency stimulation, SSCs: spontaneous synaptic current, ESCs: evoked synaptic current, CR-proBDNF: cleavage resistant proBDNF, ko: knock out, ki: knock in, DCG: 
dendritic cell granule; MMPs= matrix metalloproteinases. 
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 Table  6 *. Characteristics of each study who investigated precursor forms of BDNF in humans. 
Authors Sample Collection Subjects 
Neuropsychological 
assessment  
Antibodies/ 
Chemicals 
Principal Findings 
Michalski et 
al., 2003 
Postmortem parietal 
cortex samples 
AD= 7; HC=8 MMSE Santa Cruz Biotechnology Reduction proBDNF 40% in parietal cortex 
Weickert et 
al., 2003 
Postmortem DLPFC Schizophrenia  ______ Chemicon  
A significant reduction in BDNF mRNA (mean = 23%) and protein (mean = 
40%) in the DLPFC of patients with schizophrenia compared to normal 
individuals. 
Peng et al., 
2005 
Postmortem parietal 
cortex samples 
MCI=17; AD=17 MMSE, CGS Santa Cruz Biotechnology 
proBDNF decreased 21 and 30% in MCI and AD, respectively. mBDNF was 
reduced 34 and 62% in MCI and AD, respectively. proBDNF and mBDNF 
levels were positively correlated with cognitive measures such as the GCS 
and the MMSE score.  
Dunham et 
al., 2009 
Postmortem hippocampus 
samples 
Schizophrenia, 
MDD, BPD 
______ Santa Cruz Biotechnology 
In schizophrenia, although mean (pro)BDNF densities were lower than 
controls in most subregions, they did not reach significance. 
Wong et al., 
2010 
Postmortem 
hippocampus, DLPFC, 
parietal cortex samples 
Schizophrenic 
pts=71; hc=71 
______ Santa Cruz Biotechnology 
BDNF protein expression is reduced in the DLPFC of patients with 
schizophrenia. 
Carlino et al., 
2010 
Serum samples 
Schizophrenic 
pts=40; hc=40 
Trail Making Test A, B, Digit Span, 
Letter-Number Sequencing, Digit 
Symbol Coding subtests of  WAIS. 
The IQ was determined using the 
short form of the WAIS. 
PANSS 
Promega  
A slight reduction in serum BDNF levels in SZ patients with respect to HC. 
Increased serum pro-BDNF and mat-BDNF and reduced truncated-BDNF in 
SZ with respect to HC. Patients with an increase in pro-BDNF  or mat-BDNF  
higher than the HC mean + 2 SD also had >2SD reduction of truncated-
BDNF. 
Reduced truncated-BDNF correlated significantly with higher positive and 
lower negative PANNS scores and a worst performance in all cognitive 
assays but not with antipsychotic type. 
 
*PANSS=Positive And Negative Syndrome Scale, WAIS, NPV=Negative Predictive Value, PPV=Positive Predictive Value, MCI=Mild Cognitive Impairment, AD=Alzheimer Disease, NCI=No 
Cognitive Impairment, Pts=Patients, DLPFC= Dorsolateral Prefrontal Cortex, MMSE=Mini Mental State Examination, CGS=Global Cognitive Score; PSA-NCAM= polysialylated-neural cell adhesion 
molecule 
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7. Methods and materials 
 
7.1. Subjects 
 
The study was approved by the local Ethics Committee.Written informed consent 
was obtained from all participants or, their first degree relatives. Subjects were 
Caucasians chronic outpatients with a Diagnostic and Statistical Manual of mental 
disorders Version-IV (DSM-IV) diagnosis of schizophrenia and fulfilled the criteria for 
the Structured Clinical Interview for DSM disorders version-I (SCID-I). Patients with a 
history of substance or alcohol abuse, personality disorder, medical or neurological 
disease, dementia or mental retardation were excluded. Psychiatric symptoms were 
rated using the Positive and Negative Syndrome Subscale PANSS (Kay et al., 1989). 
Clinical subtypes of schizophrenia were as follows: residual, 9 (22.5%); paranoid, 10 
(25,0%); catatonic, 2 (5.0%); hebephrenic, 1 (2.5%); disorganized, 6 (15.0%); 
undifferentiated, 12 (30.0%). The mean antipsychotic daily dose use was 424.6 _ 
270.4 (milligrams of chlorpromazine equivalents). The average duration of 
antipsychotic treatment was 4.47 þ 3.43 years at the time of investigation. Treatment 
consisted of monotherapy with atypical antipsychotic (n=24) or typical antipsychotics 
(n ¼ 6), and 10 patients received multiple drugs simultaneously (typical þ atypical). 
Typical antipsychotics were: haloperidol (n=4), Zuclopenthixol (n=2), haloperidol 
decanoate (n=2). Atypical antipsychoticswere: olanzapine (n¼10), risperidone (n=6), 
quetiapine (n=8). The combined therapy consisted in: olanzapine þ Zuclopenthixol 
(n=1), olanzapine þ haloperidol (n=2), quetiapine þ haloperidol (n=2), quetiapine þ 
Zuclopenthixol (n=2), risperidoneþhaloperidol (n=3). In addition 23 patients received 
one (n=15) or two (n=8) antiparkinsonian drugs. Other drugs taken by the patients 
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included antibiotics, antihypertensives and gastro-protectors, but not anticoagulants. 
Antidepressant and/or mood stabilizers were not used by this patient population. 
Forty healthy control Caucasians subjects matched to patients for age, gender and 
ethnicity were recruited. None presented a personal or family history of psychiatric 
disorder (SCID nonpatient edition). 
 
7.2. Neurocognitive assessments 
 
Processing speed, attention, executive function, and working memory were assessed 
by means of an abbreviated neuropsychological battery (Harvey et al., 2009) 
consisting in Trail Making Test Parts A and B, Digit Span, Letter-Number 
Sequencing, and Digit Symbol Coding subtests of the Wechsler Adult Intelligence 
Scale, 3rd edition (Wechsler, 1997). The intelligence quotient (IQ) was determined 
using the short form of the Wechsler Adult Intelligence Scale (WAIS), which includes 
vocabulary, math, picture arrangement, and block design. 
 
7.3. Measurement of serum BDNF 
 
Blood (5 ml) was collected between 8 and 9 h AM in anticoagulant- free tubes and 
maintained at RT for 1 h, followed by 1 h at 4 _C. After centrifugation at 2000 g for 10 
min at 4 _C, serum samples were stored up to 2 months at _20 _C and then 
analysed contemporarily in triplicate. Sera were diluted 1:50 in sample buffer and 
BDNF was quantified using an ELISA kit (BDNF Emax immunoassay system, 
Promega) in a microplate reader (Anthos Labtec Instrument) set at 450 nm. 
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7.4. Western-blotting 
 
Serum samples were depleted from albumin and IgGs using Qproteome Albumin/IgG 
Depletion Kit (Qiagen). Total proteins amount in purified serum samples was 
determined using Bradford assay (SigmaeAldrich,). Proteins (30 mg) were separated 
on 12% SDS polyacrylamide gels and transferred onto nitrocellulose Protran 
membranes (Whatman). After blocking (4% non-fat milk powder, 0.05% tween-20 in 
phosphate-buffered saline) at RT, membranes were incubated overnight at 4 _C with 
one anti-BDNF antibody (N-20/sc 546, Santa Cruz Biotechnology; diluted 1:600) able 
to detect all BDNF isoforms (Michalski and Fahnestock, 2003; Peng et al., 2005). 
Following incubation with anti-rabbit secondary antibody (DakoCytomation, diluted 
1:10,000), immunoreactivity was detected by chemiluminescence (Amersham 
Biosciences). Films were scanned using an Epson Scanner (Epson perfection V500-
photo) and densitometry of immunoreactive bands of 14 KDa, 28 KDa and 32 KDa 
apparent molecular weight was determined by Quantity-One software (BioRad 
Laboratories). For calibration, each gel was loaded with 200 pg of recombinant 
human BDNF and only films with comparable intensity of this band were used. To 
avoid signal saturation, densitometry was performed at 12 bit. The relative amount of 
single proteic BDNF isoforms was evaluated by densitometrical analysis of the single 
bands Pro-BDNF, truncated-BDNF e Mature BDNF. The abundance of each BDNF 
isoform for each subject was expressed as a percentage of this isoform with respect 
to total BDNF in the same subject, calculated as follows: [densitometric value of a 
given BDNF-isoform/sum of the densitometric values (Pro-BDNF þ truncated-BDNF þ 
Mat BDNF)] _ 100. We used selected areas of equal surface and quantified the 
integrated density for each isoforms. We subtracted from each band the specific 
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background signal collected from each film developed. We verified that all purified 
sera where loaded on western-blot in comparable amount (_10%) using the 
PonceauS staining (2% in TCA, SigmaeAldrich). However, a normalization for 
loading was not necessary because we calculated the ratio within-subject. 
 
7.5. Statistical analysis 
 
Statistical analyses were performed using the Statistical Package for the Social 
Sciences, SPSS 15.0 software (SPSS Inc.). The Kolmogorov-Smirnov test was 
employed to analyse the distribution of populations. Patients and healthy controls‘ 
continuous data were compared using the Student‘s t test and the ManneWhitney U 
test, as appropriate. The c2 test was used to compare categorical data. Statistical 
significance was set at 0.05 (two tailed). To quantify statistical differences in serum 
BDNF levels between patients and healthy donors first, ELISA data on total serum 
BDNF were evaluated by U-ManneWhitney test and then, Western-blot data on 
BDNF isoforms relative abundance were statistically analysed using one-way 
ANOVA and pairwise multiple comparison procedure. Partial correlation analysis was 
used to analyse association between clinical and neuropsychological measures 
controlling for age and length of illness (Statistical significancewas set at p < 0,05). 
Multivariate analysis of covariance (MANCOVA) was used to detect differences 
between groups of patients assuming typicals, atypicals or both in terms of serum 
pro-BDNF isoforms/total BDNF ratio, with age, gender and duration of therapy as 
covariates. Spearman‘s correlations between cognitive data and mature BDNF, 
truncated-BDNF 28 KDa and precursor of 32 KDa were performed within each group. 
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7.6. Calculation of test performance 
 
Positive individuals had values >2D or <2SD with respect to the mean value in the 
normal healthy population. Schizophrenic patients (SZ) positive to test are true 
positive (=a), healthy controls (HC) which tested positive are false positive (=b), SZ 
that tested negative are false negative (¼c) while HC that tested negative are true 
negatives (¼d). Sensitivity, calculated as a/(a þ c), measures the proportion of actual 
positives which are correctly identified as such. Specificity, calculated as d/(d þ b) 
measures the proportion of negatives which are correctly identified. The positive 
predictive value is the probability a test-positive is a true positive: a/(a þ b). The 
negative predictive value is the probability a test-negative is a true negative: d/(c þ d). 
 
8. Results 
 
We studied a group (n=40) of chronic SZ patients in comparison with a 
demographically matched healthy controls group (HC, n=40) with comparable 
male/female ratio (20/20), age, years of education, BMI, and smoking habits. SZ 
subjects enrolled in the study had evidence of continued illness (mean illness 
duration 23.05 years _ 10.99), a score on Positive and Negative Syndrome Scale 
(PANNS; Kay et al.,1989), and significantly reduced IQ with respect to HC. All SZ 
patients were under treatment with typical or atypical antipsychotics monotherapy or 
combined therapy (see Methods for details). Neurocognitive performances, 
measured using an abbreviated neuropsychological assessment (Harvey et al., 
2009), were significantly different between HC and SZ groups (p < 0.0001). 
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Table 7. Socio-demographic, clinical and neurocognitive characteristics and serum BDNF levels of the 
sample. 
 
8.1 Measurement of serum BDNF 
 
As measurement of serum BDNF is influenced by total serum protein concentration 
and number of platelets (Karege et al., 2005) we measured these serum parameters 
in HC and SZ and found no differences between the two groups. We also did not find 
any significant gender difference between BDNF serum values of healthy donors, as 
reported previously (Ziegenhorn et al., 2007). The SZ group showed a slightly lower 
mean serum concentration of BDNF measured by ELISA, with respect to the HC 
group (Table 1, Fig. 1; p < 0.018). However, by comparing the distribution of serum 
concentrations for BDNF in HC and SZ subjects, it was evident that the two 
populations had an overlapping range of values. These results confirmed that it is 
practically impossible to discriminate between SZ and HC only on the basis of BDNF 
serum levels. Hence, we investigated by Western-blot analysis the abundance of the 
different BDNF isoforms in the serum of these two groups. Recombinant human mat-
BDNF and pro-BDNF precursor were loaded as positive controls (first two lanes). 
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Densitometric analysis ofWestern blots (n=40 HC, n=40 SZ, each in duplicate), 
showed that with respect to HC, SZ subjects had significantly more pro-BDNF (SZ 
47.31% _ 9.05, HC 32.72% _ 9.27; p < 0.001), more mat-BDNF (SZ 31.07% _ 8.69, 
HC 26.26% _ 5.69; p < 0.001) and reduced truncated-BDNF (SZ 21.62% _ 10.04, HC 
41.01% _ 8.6; p < 0.001. Values are expressed as % of total BDNF, see Methods). 
For comparison with other studies using antibodies against the proregion common to 
both pro-BDNF and truncated-BDNF, we also calculated the relative abundance of 
prototal given by the sum of pro-BDNF and truncated BDNF and found a significant 
decrement in SZ patients with respect to HC. To analyse individual variability, three 
scatter plots were generated, for pro-BDNF, truncated BDNF and mat-BDNF, 
respectively and patients were subdivided in subgroups using as reference the mean 
value of the HC group and corresponding standard deviation values (SD, Fig. 2C,D 
and E). Although some SZ patients had BDNF isoforms abundance comparable to 
those of HC, we found three subgroups of SZ subjects with clearly altered values. 
The first subgroup, consisting in 15 out of 40 SZ subjects, was characterized by pro-
BDNF values greater than the HC mean þ 2SD. The second subgroup (n = 9/40 SZ 
subjects) showed mat-BDNF values greater than the HC mean þ 2SD  and the third, 
more numerous, subgroup (n=27/40) comprised SZ subjects with truncated-BDNF 
values lower than the HC mean-2SD. Interestingly, each SZ patient with mat-BDNF 
(Group 1) or pro-BDNF (Group 2) levels greater than the HC mean þ 2SD (>2SD), 
also had a reduction in truncated-BDNF with values lower than the HC mean-2SD 
(<2SD). However, these two groups (Group 1 and 2) were distinct because we never 
found a case in which both mat-BDNF and pro BDNF were significantly increased at 
the same time. Of note, these two subgroups were not significantly related to a 
particular atypical and/or typical antipsychotic therapy (X2 =0.940, df ¼ 2, p ¼ 
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0.625). In conclusion, this analysis underlined that every patient with truncated-BDNF 
levels lower than HC mean-2SD also had significantly altered amount of pro-BDNF or 
mat-BDNF. Thus, to detect both Group 1 and 2 SZ patients with an unbalance in 
BDNF isoforms levels, it is sufficient to quantify serum truncated-BDNF. 
 
 
 
Figure 11. BDNF serum values. Box plot of serum BDNF concentration (pg/ml) in healthy human 
volunteers (Controls, n = 40) and schizophrenic patients (Schizo, n = 40). The upper line of the box 
corresponds to the 75th percentile (Q3), the middle line is the median value and the lower line marks 
the 25th percentile (Q1). HD Controls median = 28.9; Q1-Q3 = 22.0-32.1. Schizophrenic patients 
median = 25.5; Q1-Q3 = 23.1-27.8. Whiskers (error bars) above and below the box indicate the 90
th
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and 10th percentiles. Dots indicate the highest and lowest value within each group. * = p < 0.018, 
ManneWhitney U test. 
 
8.2. Association of truncated-BDNF levels to cognitive impairment 
 
Since not all SZ patients had reduced truncated-BDNF, we investigated if there were 
differences between SZ with normal truncated-BDNF (13/40) and those with reduced 
truncated-BDNF (27/40). SZ with low truncated-BDNF had a longer disease duration 
and significantly higher positive and lower negative PANNS scores, but were not 
different in PANSS general symptoms and total score with respect to SZ with normal 
truncated-BDNF. We found that in SZ patients, low truncated-BDNF expression 
correlates with worse performance on Trail Making Test Part B (r = 0.553; p < 
0.0001), Digit Symbol Coding (r¼_0.360; p ¼ 0.046) and Digit Span Forward 
(r<_0.360; p < 0.024) but not Trail Making Test part A. Moreover, within the group 
with reduced truncated- BDNF, we found a significant correlation between PANSS 
Negative Symptoms scores and neurocognitive tests scores except for Trail Making 
Test Part A (p < 0,05). Finally, we also examined cognitive functioning of healthy 
control subjects with low truncated-BDNF and observed reduced performances in 
three out of four subjects on test of information processing (Trail Making Test B; case 
1: 150; case 2: 148; case 3: 150; case 4: 143; see median and 25e75 percentiles of 
HC subjects) and in all four individuals on attention (Symbol Digit Coding; case 1: 50; 
case 2: 51; case 3: 52; case 4: 52; compare with HC values), even if the low number 
of cases was insufficient for statistical analysis. The subgroup of SZ patients with 
elevated pro-BDNF (>2SD; Group 1), comprised only subjects who also had reduced 
truncated-BDNF. Notably, Group 1 SZ patients with elevated pro-BDNF (15/40 
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subjects) showed the same clinical features of the group with reduced truncated-
BDNF. We concluded that augmented pro-BDNF and decreased truncated-BDNF 
represent two complementary aspects of the same phenotype. However, a subgroup 
of 9 patients with decreased truncated- BDNF had increased mat-BDNF but normal 
pro-BDNF (Group 2). Comparative analysis of the clinical features between 
subgroups revealed that Group 2 patients with increased mat-BDNF, were younger 
(median 47 years vs. 59) but with significantly longer disease duration (median 31 
years vs. 22) with respect to Group 1 patients with augmented pro-BDNF, and were 
not significantly different with respect to PANSS and cognitive assessment scores. 
Since antipsychotics can cause a decrease in serum BDNF levels (Jindal et al., 
2010), we used multivariate analysis of covariance (MANCOVA) to detect differences 
between groups of patients assuming typicals, atypicals or both in terms of BDNF 
isoforms/total BDNF ratio, with age, gender and duration of therapy as covariates. 
MANCOVA analysis showed that there was no difference between types of 
antipsychotic medication for the variance of pro-BDNF/tot-BDNF (F = 0.333, df = 2, p 
= 0.719), truncated-BDNF/tot-BDNF (F = 1967, df = 2, p = 0.155), total pro-BDNF/tot-
BDNF (F = 0.699, df = 2, p < 0.504) or mature BDNF/tot-BDNF (F = 0.699, df = 2, p < 
0.504). In conclusion, decreased abundance in serum truncated-BDNF BDNF 
predicts specifically for higher cognitive deficits in schizophrenia and we found a 
substantial homogeneity in the clinical features of SZ patients with reduced 
truncated-BDNF, irrespective of whether they also had a concomitant increase in 
mat-BDNF or pro-BDNF, or antipsychotic therapy used. We evaluated then, if 
measurement of serum truncated-BDNF could be used as an empirical method to 
predict for cognitive impairment in both healthy and schizophrenic subjects. This 
hypothetical test, considering a cut-off at 2SD from the mean value of healthy 
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controls (i.e., when truncated-BDNF is below 23,79% of the total BDNF serum 
concentration), has a sensitivity of 67.5% (27/40 SZ are true positive = a, and 13/40 
SZ are false negative = c; see Methods), and 97.5% specificity (1/40 HC are false 
positive = b, thus 39/40 HC are true negative = d; see Methods). Positive Predictive 
 Value is 96.4% and Negative Predictive Value 75% (see Methods). In sum, this test 
is a very good inclusion test as all subjects with truncated-BDNF below 23,79% are 
certainly having cognitive impairment. 
 
Figure 12. BDNF isoforms in the serum of healthy subjects and chronic patients with schizophrenia. 
A) Western-blot with sc-546(N-20) anti-BDNF antibody to determine the ratio between pro-BDNF and 
mature BDNF in healthy controls (HC) and schizophrenic patients (SZ). First two lanes, 500 pg of 
recombinant human mature BDNF (mat), and 500 pg of recombinant human pro-BDNF (pro). 
Following lanes, 30 mg of serum proteins of HC or SZ were loaded. Bars with 34 KDa, 26 KDa and 17 
KDa indicate position of molecular markers and their relative approximate weight. B) Relative 
percentage of pro-BDNF, truncated-BDNF or mature BDNF with respect to the total amount of serum 
BDNF (total BDNF is calculated as the sum of pro-BDNF þ truncated-BDNF þ mature BDNF 
densitometric values for each patient). Pro-Total BDNF is the sum of pro- and truncated-BDNF. (CeE) 
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Scatter plots showing the distribution of the percentage of pro-BDNF (C), truncated-BDNF (D) or 
mature BDNF (E). Lines within the scatter plot, mark the mean percentage value in the HC group 
(mean) and the mean plus 1, or 2 standard deviations (1SD, 2SD). * = p < 0.05; ** = p < 0.001; *** = p 
< 0.0001 one-way ANOVA (HolmeSidak). 
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Figure 12. Schematic summary of findings. A) The relative abundance (%) of BDNF isoforms in healthy control (HC) subjects is reported in grey boxes. 
Cleavage site 1, which generates the truncated-BDNF of 28 KDa form, is cleaved by the SKI-1 protease, while cleavage site 2, which generates mature 
BDNF, can be recognized by three proteases, furin, MMP-7 and plasmin. B) In Group 1 SZ patients with high cognitive impairment, truncated-BDNF is 
reduced and uncleaved pro-BDNF precursor is increased, most likely as a result of a reduced cleavage at site 1 while mature BDNF is in normal amounts. In 
Group 2 SZ patients with high cognitive impairment, truncated-BDNF is also reduced but pro-BDNF is normal (¼no significant variations with respect to 
healthy controls), most likely due to a compensatory increase of cleavage at site 2 to generate mature BDNF which results increased. As Group 2 patients had 
longer disease duration with respect to Group 1, this compensatory mechanism may occur after a prolonged pathological condition. Grey boxes report the 
relative abundance (%) of serum BDNF isoforms which is significantly predictive for high cognitive impairment. 
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Table 8. Association of reduced pro28 BDNF with worst PANNS symptoms and greater cognitive impairment. 
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9. Discussion 
 
In this study we provide evidence that reduced levels of serum truncated-BDNF/total 
BDNF ratio correlate with worst PANSS negative and positive symptoms and poorer 
neurocognitive performance. Instead, measurement of total serum BDNF levels 
resulted poorly informative, even if we found a small decrease in the whole 
population of schizophrenic patients. We further show that when using a cut-off at 
mean _ 2SD from the healthy group, measurement of relative amount of serum 
truncated-BDNF provides a novel empirical test to identify schizophrenic patients with 
high cognitive deficits, with sensitivity ¼ 67.5%, Specificity ¼ 97.5%, PPV ¼ 96.4% 
and NPV ¼ 75%. Regulated proteolysis of one inactive precursor to produce active 
peptides and proteins is a general mechanism to generate biologically diverse 
products from a single gene. Mammalian pro BDNF precursor is processed to 
generate truncated-BDNF 28 KDa or mature 14 kDa BDNF by two different proteolitic 
cleavages. Mature BDNF is generated intracellularly by furin (Mowla et al., 2001), or 
extracellularly, by plasmin or matrixmetalloprotease-7 (Lee et al., 2001). Truncated-
BDNF is generated by a specific Ca2þdependent serine proteinase known as 
Membrane-bound transcription factor site-1 protease (MBTFS-1), also known as 
Subtilisin/kexin-isozyme 1 (SKI-1) (Seidah et al., 1999) and since is not further 
processed into the mature 14 kDa BDNF form, it represents a true final proteolytic 
product whose function is unclear. Recent studies have demonstrated that mature 
and pro-BDNF elicit opposite biological effects (Teng et al., 2005; Woo et al., 2005), 
leading to the conclusion that an incorrect balancing of the different isoforms may 
cause a pathological effect.  
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More recently, Koshimizu et al. (2009) reported that overexpression of pro-BDNF 
elicited apoptosis of cultured cerebellar granule neurons and caused a dramatic 
reduction in the number of cholinergic fibers of basal forebrain neurons and 
hippocampal dendritic spines, without affecting the survival of these neurons. 
Blockade of activation of p75 receptor prevented spine number reduction. Of note, 
the pro-BDNF preparation used by these authors consistently contained truncated 
BDNF, albeit at a much lesser extent than pro-BDNF. It is therefore conceivable that 
truncated-BDNF may have a similar effect than pro-BDNF through formation of 
homodimers. As a possible alternative, truncated-BDNF ay be an inactive form of pro 
BDNF or act as a quencher of pro-BDNF by forming inactive heterodimers. The latter 
hypothesis recalls the proposed role for truncated-TrkB. Hence, a marked reduction 
in truncated-BDNFmay lead to pathological increased signalling of pro-BDNF. Here, 
we provide evidence that 2/3 of schizophrenic patients present an altered regulation 
of the 28 KDa BDNF truncated proteolytic product. Further studies will be required to 
elucidate the biological role of truncated-BDNF. We must emphasize that all patients 
with reduced truncated-BDNF BDNF showed either increased pro-BDNF (Group 1) 
or increased mat BDNF (Group 2) but not both. Fig. 12 shows a possible model to 
explain how this dysregulation might occur. In Group 1 SZ patients, reduced 
cleavage at site 1 produces less truncated-BDNF and results in accumulation of 
uncleaved pro-BDNF precursor while cleavage at site 2 is unaffected and therefore, 
mature BDNF levels are normal. In Group 2 SZ patients, even if truncated-BDNF is 
reduced like in Group 1 patients, the increase in pro-BDNF does not occur, most 
likely due to a compensatory increase in processing of this precursor to generate the 
mature 14 KDa form. Indeed, in Group 2 SZ patients we observed an increase in 
mature BDNF. Considering that this increase is noticed in Group 2 SZ patients with 
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longer disease duration (median 31.5 vs. 22 years in Group 1), it is possible to 
hypothesize that this compensatory mechanism may occur after a prolonged 
pathological condition, and does not operate in Group 1 SZ patients. These 
observations warrant further investigations to determine whether the unbalance in 
serum BDNF isoforms is due to altered expression or efficiency of proteases, serum 
protease inhibitors levels or mutations at BDNF cleavage sites. Chronic 
schizophrenic patients are consistently found to undergo progressive substantial 
intellectual deterioration at below average levels of functioning (Heinrichs, 2006). In 
our study, SZ patients with reduced truncated-BDNF had worse performance in all 
neurocognitive tests with respect to the other patients with normal levels of truncated-
BDNF, although no significant correlation was found between Trail Making Test Part 
A score and truncated-BDNF abundance in patients with schizophrenia. Our results 
further extend a recent study suggesting that measurement of total serum BDNF may 
be of use to monitor for a successful training for cognitive enhancement in 
schizophrenic patients (Vinogradov et al., 2009). Of note, we also found that four 
healthy controls with low truncated-BDNF had poor scores in Trail Making Test B and 
Symbol Digit Coding attention test. On the basis of our findings it is expected that SZ 
patients with low serum truncated-BDNF (and worse cognitive impairment) are likely 
to be more refractory to a non-pharmacological cognitive rehabilitation therapy. We 
used six neuropsychological tests that are consistently correlated with functional 
outcomes. In particular, four out of these six measures explained 74% of variance in 
the composite score analysis (Harvey et al., 2009). Notably, we found in SZ patients 
with reduced truncated-BDNF a significant association between higher PANSS 
Negative Symptoms scores and worse neurocognitive tests scores except in Trail 
Making Test Part A. A recentmeta-analysis (Dickinson et al., 2007) reported that 
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reduced processing speed performance at the digit symbol coding task represents 
the greatest deficit among cognitive abilities in patients with schizophrenia and there 
is cleavage at site 1 while mature BDNF is in normal amounts. In Group 2 SZ 
patients with high cognitive impairment, truncated-BDNF is also reduced but pro-
BDNF is normal (¼no significant variations with respect to healthy controls), most 
likely due to a compensatory increase of cleavage at site 2 to generate mature BDNF 
which results increased. As Group 2 patients had longer disease duration with 
respect to Group 1, this compensatory mechanism may occur after a prolonged 
pathological condition. Grey boxes report the relative abundance (%) of serum BDNF 
isoforms which is significantly predictive for high cognitive impairment. 
 
10. Future research proposals 
 
The hypothesis that relapse could be predicted by low neurotrophin levels is 
consistent with the neurobiology of relapse and with preliminary data in first episode 
psychosis patients (Parikh et al., 2003). Therefore, large populations of high-risk 
subjects or untreated first episode patients need to be longitudinally investigated to 
improve the statistical importance of the analysis (Pantelis et al., 2003). In fact, in the 
absence of a neuroleptic naïve cohort followed longitudinally to evaluate pattern of 
neurotrophins over time, it is difficult to determine whether any relationship between 
relapse and low neurotrophins would be due to an underlying neurobiological 
vulnerability to relapse, an inadequate therapeutic response to antipsychotics, or 
inadequate antipsychotic exposure due to medication noncompliance. In the first part 
of the meta-analysis, serum BDNF levels were shown to be reduced in patients with 
schizophrenia even if the difference was moderately significant (p<0.05). However, 
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considerable statistical heterogeneity was detected between studies. In the second 
part of the meta-analysis, we found that serum BDNF levels in patients with drug 
free/first episode psychosis were significantly lower in patients compared to healthy 
control subjects, but we could not detect any significant alteration in serum BDNF 
levels in patients with chronic schizophrenia. In both cases, a high heterogeneity was 
between the studies was highlighted and it is still unclear whether the reduction in 
serum BDNF levels observed in drug naïve/first episode patients with schizophrenia 
is due more to antipsychotic treatment or toxic effect of psychosis in itself. Therefore, 
future biochemical studies should longitudinally investigate larger samples of high-
risk individuals, drug free first-episode patients and unaffected family members. Such 
populations are crucial to systematically examine whether serum BDNF levels 
changes are already present before the appearance of symptoms, or whether they 
develop afterwards, as a result of the course of illness. Such biochemical studies, 
should be crossed with MRI, genetic and metabolism investigations data, in order to 
further investigate whether serum BDNF levels represent an indicator of vulnerability 
to the disease and to better understand the functional expression of serum BDNF 
levels abnormalities in schizophrenia. 
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11. Conclusions 
 
Taken together, these findings suggest that the processing of precursors of BDNF 
may be a key regulator of synaptic plasticity which is the neurobiological 
underpinning of brain remodeling and cognitive functioning. The preclinical studies 
reviewed here pointed to the role of  of aging on BDNF proteolytic processing, which 
may have a significant impact on others biological cascades (i.e. Beta-amyloid or 
LPS-mediated inflammatory processes). Changes in BDNF catabolism may have    
an  additive and/or multiplicative neuropathological effect on brain‘s structure,  thus 
perpetuating neurodegenerative events in schizophrenia as well as AD. Indeed, 
neuroimaging studies showed volumetric reduction at the level of the hippocampus 
and frontal lobe in schizophrenia, and similar findings were observed in AD. In AD, 
serum BDNF changes  may also indicate a progressive shift toward a 
neurodegenerative state in the healthy elderly subjects and progression from aMCI to 
AD. It is plausible to hypothesize that, in complex neurodegenerative diseases, 
protective and deleterious biochemical cascades are in a delicate homeostatic 
balance that is tightly controlled and, thus, neurodegeneration results from an 
imbalance between these cascades. Respect to schizophrenia, convergent evidence 
of age-related decline in blood and brain BDNF might therefore reflect an accelerated 
decline in normal age-related BDNF decrease. In addition, a great number of studies 
sustain that a significant reduction of peripheral and CNS BDNF levels occurs  early 
in the development of schizophrenia brains. Moreover, this reduction is more 
consistent than that observed in healthy subjects during aging. Modern 
pathophysiological hypotheses of schizophrenia postulate both neurodegenerative 
and neurodevelopmental process modify brain structure and participate in the 
66 
 
development of clinical symptomatology. To date, there are several brain tissue 
morphological alterations deriving from abnormal neural organization (i.e esempi con 
riferimenti letterari) in schizophrenia. However some regions may face a further 
degeneration, as the dopaminergic pathways directed to the cortex and glutamatergic 
pathways directed from the cortex to subcortical structures. This neurobiological 
events may explain the progressive resistance to antipsychotic medications and 
worsening of cognitive impairment. Degeneration may be also encouraged by 
positive symptoms in psychotic relapse, as they have a neurotoxic impact. Expanding 
the Buckley point of view (Buckley, 2007), BDNF metabolism is both a ‗biological 
footprint‘ of relapse in schizophrenia and a plausible endophenotype of ―cognitive 
stress‖: a strain in cognitive function or processing certain information/messages sent 
to the brain. Although the role of different BDNF isoforms remains to be elucidated, 
we ,we  may speculatethat truncated-BDNF have a similar outcome than pro-BDNF 
through activation of the same signaling pathways. Alternatively, truncated-BDNF 
may be an inactive variety of pro-BDNF or operate as a quencher of pro-BDNF by 
producing inactive heterodimers.. Hence, a clear decrease in truncated-BDNF may 
direct to pathologically amplified signaling of pro-BDNF. Further studies will be 
necessary to clarify the biological characteristics of truncated-BDNF. Therefore, the 
activity of proteases mediating BDNF processing may be considered a compensatory 
neurotrophic mechanism, partly explaining  etiopathogenesis, early diagnosis, 
treatment and prognosis of schizophrenia and AD. 
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